Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (141-150 of 284) with videos related to

Pageof 29
Sort By:
British Journal of Cancer|November 18, 2015
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancerFotios Loupakis, Roberto Moretto, Giuseppe Aprile, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Mirella Giordano, Anello M Poma, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i> <sup></sup> -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2026
Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trialAdrien Grancher, Matteo Landi, Alexej Ballhausen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trialsCarlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
Pageof 29

Showing results (141-150 of 284) with videos related to

Sort By:
Pageof 29
British Journal of Cancer|November 18, 2015
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancerFotios Loupakis, Roberto Moretto, Giuseppe Aprile, et al.
Journal for Immunotherapy of Cancer|April 21, 2023
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE studyRoberto Moretto, Daniele Rossini, Aurélie Catteau, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 studyRoberto Moretto, Mirella Giordano, Anello M Poma, et al.
British Journal of Cancer|October 7, 2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONODaniele Rossini, Sara Lonardi, Carlotta Antoniotti, et al.
JCO Precision Oncology|April 18, 2025
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal CancerRoberto Moretto, Marco Maria Germani, Martina Carullo, et al.
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Therapeutic Advances in Medical Oncology|January 8, 2025
Prognostic impact of depth of response and early tumour shrinkage in patients with <i>BRAF</i> <sup></sup> -mutated metastatic colorectal cancer treated with targeted therapyGuglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 2, 2026
Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 - PRODIGE 107 - FFCD 2306 - COLOSOTO trialAdrien Grancher, Matteo Landi, Alexej Ballhausen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trialsCarlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
Pageof 29